Early larval stages of C. elegans (L1 to L3 and Dauer) have always been among the hardest to immobilize and image successfully, due to their tiny size and difficulties with using conventional anesthetics and time-consuming mounting methods. To help researchers solve these problems, Newormics is launching two new devices in our vivoChip™-2x range: vivoChip™-2x L1-L2, Read more about Newormics launches new <em>vivo</em>Chips for early stage worms[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Environmental Health Sciences (NIEHS) for the project “A Large-Scale Microfluidics Imaging Platform for High-Throughput Toxicity Testing using Canine Intestinal Organoids”. Currently, toxicology studies require a large number of animal testing to identify better and safer drug candidates. In an attempt to reduce Read more about Newormics awarded an SBIR Phase I grant from the NIEHS[…]
Newormics is exhibiting at the 22nd International C. elegans Conference at UCLA, Los Angeles from 20th June – 24th June. Come and meet the team here at our booth.
Newormics was selected for the NIH I-Corps April-June 2019 cohort. Over the course of the I-Corps program, the team had conversations with over 100 stakeholders in the field. This helped the company gather vital market research to understand the needs and pain points of potential customers, and improve Newormics product lines The program finale was Read more about Newormics selected for the NIH I-Corps[…]
Newormics was awarded an SBIR Phase I grant from the National Institute of Mental Health (NIMH) for the project “A multi-well plate format microfluidic immobilization chip for high-content imaging of whole animals”. Advancements in precise genetic manipulation have helped biologists to identify new drug-targets and in vivo disease mechanisms using small animal models, such as Read more about Newormics awarded SBIR Phase I grant from the NIMH[…]
Newormics is a developer of the first high-throughput, high-content drug screening platforms for use with in vivo small animal models as well as 3D tissue organoids. The company provides microfluidics-based platforms to advance early stage drug discovery and toxicity studies for faster and better drug development with cost-effective solutions. Newormics is co-founded by Prof. Adela Read more about Introducing the Next Generation Drug Discovery Platforms[…]